Dutch diagnostics giant Qiagen ($QGEN) grabbed Ingenuity Systems in a $105 million cash deal, giving it new technology to boost the analysis of genomic data for molecular diagnostics.
Ingenuity, based in Redwood City, CA, brings a number of new product innovations to the table, including its Ingenuity Knowledge Base database, which organizes data concerning, in part, genetic variations in human disease. In addition, Ingenuity's software helps guide clinical trials and medical treatment decisions.
Qiagen CEO Peer Schatz said in a statement that the Ingenuity acquisition will help boost its molecular diagnostics capacity to interpret biological information, helping it to build "a leading role in this field."
"Integration of Ingenuity's solutions into a powerful, full-range ecosystem of Qiagen's molecular testing solutions, such as PCR and next-generation sequencing, promises to offer significant value to Qiagen customers and shareholders," Schatz said.
Beyond molecular diagnostics, Qiagen is also focused on applied testing, pharmaceutical and academic research-related diagnostic tools. But the company has focused on growing its molecular diagnostics side. Earlier this year, for example, Qiagen expanded its partnership with Eli Lilly ($LLY) to develop companion diagnostics in a number of different disease areas. It also inked a similar deal with Bayer focused on solid tumor treatments. And the company is awaiting FDA approval for a lung cancer drug companion diagnostic developed to go with a Boehringer Ingelheim investigational drug treatment.
- read the release